Heterogeneous alterations in human alloimmunity associated with immunization

Transplantation

Volumn 80, Issue 3, 2005, Pages 297-302

  Roddy, Meagan ^a   Clemente, Michael ^a   Poggio, Emilia D ^a   Bukowski, Ronald ^b   Thakkar, Snehal ^b   Waxenecker, Gunter ^c   Loibner, Hans ^c   Himmler, Gottfried ^c   Hricik, Donald E ^d   Heeger, Peter S ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c Igeneon   (Austria)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alloreactivity; Cytokine; Immunization; T lymphocyte

Indexed keywords

ALLOANTIBODY; ANTIIDIOTYPIC ANTIBODY; CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN; IGN 301; UNCLASSIFIED DRUG;

ADULT; AGED; ALLOIMMUNITY; ANTIBODY DETECTION; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME LINKED IMMUNOSPOT ASSAY; EVALUATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; ANTIBODY FORMATION; AUTOIMMUNITY; CELL LINE, TUMOR; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL NEOPLASMS; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; ISOANTIBODIES; LYMPHOCYTES; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TIME FACTORS; VACCINATION;

EID: 23744478655     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000168148.56669.61     Document Type: Article

References (23)

1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331(6): 365.
2. Illigens B, Yamada A, Fedoseyeva E, et al. The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol 2002; 63(10): 912.
3. Bolton EM, Armstrong HE, Briggs JD, Bradley JA. Cellular requirements for first-set renal allograft rejection. Transplant Proc 1987; 19 (1 Pt 1): 321.
4. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56(3): 783.
5. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280(14): 735.
6. Vassalli G, Gallino A, Weis M, et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003; 24(13): 1180.
7. Zerbe T, Uretsky B, Kormos R, et al. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant 1992; 11 (3 Pt 2): S104.
8. Pelletier RP, Hennessy PK, Adams PW, et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002; 2(2): 134.
9. Petrossian GA, Nichols AB, Marboe CC, et al. Relation between survival and development of coronary artery disease and anti-HLA antibodies after cardiac transplantation. Circulation 1989; 80 (5 Pt 2): III122.
10. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003; 3(7): 878.
11. Gebauer BS, Hricik DE, Atallah A, et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2(9): 857.
12. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163(4): 2267.
13. Poggio ED, Clemente M, Riley J, et al. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 2004; 15(7): 1952.
14. Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002; 2(6): 501.
15. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003; 3(12): 1488.
16. Baron C, Pastural M, Lang P, et al. Long-term kidney graft survival across a positive historic but negative current sensitized cross-match. Transplantation 2002; 73(2): 232.
17. Speiser DE, Jeannet M. Renal transplantation to sensitized patients: decreased graft survival probability associated with a positive historical crossmatch. Transpl Immunol 1995; 3(4): 330.
18. Mazzone PJ, Mossad SB, Mawhorter SD, et al. Cell-mediated immune response to influenza vaccination in lung transplant recipients. J Heart Lung Transplant 2004; 23(10): 1175.
19. van Besouw NM, van der Mast BJ, de Kuiper P, et al. T-cell reactivity during azathioprine therapy compared with mycophenolate mofetil therapy. Transplant Proc 2001; 33(3): 2239.
20. Scanlon-Kohlroser CA, Fan PY, Primack W, Stoff JS. Primary varicella after transplantation. Am J Kidney Dis 2002; 39(6): 1310.
21. Vilchez RA, Fung J, Kusne S. The pathogenesis and management of influenza virus infection in organ transplant recipients. Transpl Infect Dis 2002; 4(4): 177.
22. Kumar D, Rotstein C, Miyata G, et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187(10): 1639.
23. Cavdar C, Sayan M, Sifil A, et al. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol 2003; 37(1): 71.